Analyse Olema Pharmaceuticals, Inc. (OLMA) — Kairos Score 59/100

À propos de Olema Pharmaceuticals, Inc.

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Informations clés

🕴️ Activité des initiés (90 jours)

0 transactions — 0 achats et 0 ventes déclarés par les dirigeants de Olema Pharmaceuticals, Inc..

🏦 Hedge Funds

15 fonds institutionnels déclarent une position sur OLMA dans leur dernière déclaration trimestrielle SEC.

📰 Actualités récentes

15 articles récents sur OLMA.

• Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
• Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results

🧠 Ce qui fait Kairos Insider

Au-dela des donnees brutes, nous agregeons et scoring tout le signal smart money pour vous donner une vue unique.